MA27647A1 - Antagonistes de ccr5 utiles comme agents therapeutiques - Google Patents

Antagonistes de ccr5 utiles comme agents therapeutiques

Info

Publication number
MA27647A1
MA27647A1 MA28386A MA28386A MA27647A1 MA 27647 A1 MA27647 A1 MA 27647A1 MA 28386 A MA28386 A MA 28386A MA 28386 A MA28386 A MA 28386A MA 27647 A1 MA27647 A1 MA 27647A1
Authority
MA
Morocco
Prior art keywords
therapeutic agents
treatment
antagonists useful
ccr5 antagonists
compounds
Prior art date
Application number
MA28386A
Other languages
English (en)
Inventor
Wieslaw Mieczyslaw Kazmierski
Christopher Joseph Aquino
Neil Bifulco
Eric Eugene Boros
Brian Andrew Chauder
Pek Yoke Chong
Maosheng Duan
Jr Felix Deanda
Cecilia Suarez Koble
Ed Williams Mclean
Jennifer Poole Peckham
Angilique Perkins
James Benjamin Thompson
Dana Vanderwall
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA27647A1 publication Critical patent/MA27647A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention porte sur des composés de formule (I) ou sur leurs dérivés acceptables d'un point de vue pharmaceutique, ces composés étant utiles dans le traitement ou la prophylaxie des maladies ou troubles liés à CCR5, par exemple, dans l'inhibition de la réplication du VIH, la prévention ou le traitement d'une infection provoquée par le VIH et dans le traitement du syndrome d'immunodéficience acquise (SIDA) en résultant.
MA28386A 2002-12-13 2005-07-13 Antagonistes de ccr5 utiles comme agents therapeutiques MA27647A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43363402P 2002-12-13 2002-12-13

Publications (1)

Publication Number Publication Date
MA27647A1 true MA27647A1 (fr) 2005-12-01

Family

ID=32595222

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28386A MA27647A1 (fr) 2002-12-13 2005-07-13 Antagonistes de ccr5 utiles comme agents therapeutiques

Country Status (15)

Country Link
US (1) US7645771B2 (fr)
EP (1) EP1569646A2 (fr)
JP (1) JP2006511554A (fr)
KR (1) KR20050087832A (fr)
CN (1) CN1744899A (fr)
AU (1) AU2003300902A1 (fr)
BR (1) BR0317230A (fr)
CA (1) CA2509711A1 (fr)
CO (1) CO5580771A2 (fr)
MA (1) MA27647A1 (fr)
MX (1) MXPA05006354A (fr)
NO (1) NO20052739L (fr)
RU (1) RU2005118407A (fr)
WO (1) WO2004054974A2 (fr)
ZA (1) ZA200505600B (fr)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215293D0 (en) * 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
WO2004054581A2 (fr) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Composes de cyclohexyle utiles en tant qu'antagonistes du ccr5
JPWO2004108662A1 (ja) * 2003-05-15 2006-07-20 クミアイ化学工業株式会社 フェニルスルホニルカーバメイト誘導体及び農園芸用植物病害防除剤
EP2161273B1 (fr) * 2003-12-22 2015-04-15 K.U.Leuven Research & Development Composés d'Imidazo[4,5-c]pyridine et procédés de traitement anti-viral
JP4958560B2 (ja) * 2003-12-24 2012-06-20 プロシディオン・リミテッド Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
SE0401657D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
NZ556624A (en) * 2004-12-21 2010-06-25 Gilead Sciences Inc 5-((3-(2,4-trifluoromethyphenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine and method of antiviral treatment
AU2012200933B2 (en) * 2005-06-22 2015-04-30 Plexxikon, Inc. Pyrrolo [2, 3-B] pyridine derivatives as protein kinase inhibitors
UA95244C2 (ru) * 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
US8097610B2 (en) 2005-08-26 2012-01-17 Shionogi & Co., Ltd. Derivative having PPAR agonistic activity
WO2007036711A1 (fr) 2005-09-30 2007-04-05 Glaxo Group Limited Benzimidazolones exerçant une activite au niveau du recepteur m1
WO2007036718A2 (fr) 2005-09-30 2007-04-05 Glaxo Group Limited Composes exerçant une activite au niveau du recepteur m1 et leurs utilisations en medecine
US8283364B2 (en) 2005-09-30 2012-10-09 Glaxo Group Limited Compounds which have activity at M1 receptor and their uses in medicine
WO2007073432A2 (fr) 2005-10-11 2007-06-28 Chemocentryx, Inc. Derives de la piperidine et procedes d’utilisation
WO2007130712A1 (fr) * 2006-01-31 2007-11-15 Janssen Pharmaceutica, Nv Composes dipiperidiniques substitues utilises en tant qu'agonistes de ccr2 dans le cadre du traitement de maladies inflammatoires
GB0605786D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
AU2007268749B2 (en) * 2006-05-26 2012-07-26 Taisho Pharmaceutical Co., Ltd. Novel heterocyclic compound or salt thereof and intermediate thereof
WO2008004100A2 (fr) 2006-07-05 2008-01-10 Pfizer Products Inc. Composés thérapeutiques
KR101143596B1 (ko) 2006-07-07 2012-05-11 길리애드 사이언시즈, 인코포레이티드 신규의 피리다진 화합물 및 이의 용도
AU2007275301A1 (en) * 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
DE602007007497D1 (de) 2006-09-18 2010-08-12 Hoffmann La Roche Octahydropyrroloä3,4-cüpyrrolderivate und ihre verwendung als antivirale mittel
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
EP2088860A4 (fr) * 2006-12-06 2010-12-22 Genzyme Corp Composés de liaison à un récepteur de chimiokine
TW200831092A (en) * 2006-12-21 2008-08-01 Astrazeneca Ab Therapeutic agents
US8012955B2 (en) 2006-12-28 2011-09-06 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
GB0718415D0 (en) 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
EP2211618A1 (fr) * 2007-10-11 2010-08-04 Glaxo Group Limited Pipéridinylhydroxyéthylpipéridines utilisables en tant que modulateurs des récepteurs aux chimiokines
WO2009051112A1 (fr) 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited Composés amides et leur utilisation
WO2009058924A1 (fr) * 2007-10-31 2009-05-07 Smithkline Beecham Corporation Antagonistes de ccr5 en tant qu'agents thérapeutiques
WO2009058923A1 (fr) * 2007-10-31 2009-05-07 Smithkline Beecham Corporation Antagonistes de ccr5 en tant qu'agents thérapeutiques
NZ585298A (en) 2007-11-16 2012-08-31 Rigel Pharmaceuticals Inc Carboxamide, sulfonamide and amine compounds for metabolic disorders
WO2009075960A1 (fr) * 2007-12-12 2009-06-18 Smithkline Beecham Corporation Antagonistes de ccr5 comme agents thérapeutiques
EP2231666B1 (fr) 2007-12-12 2015-07-29 Rigel Pharmaceuticals, Inc. Composés de carboxamide, de sulfonamide et d'amine servant a traiter les troubles métaboliques
KR20100122505A (ko) 2008-02-29 2010-11-22 어레이 바이오파마 인크. Ｒａｆ 저해물질 화합물 및 이들의 이용 방법
WO2009131957A2 (fr) 2008-04-21 2009-10-29 Institute For Oneworld Health Composés, compositions et traitements comprenant des dérivés d'oxydiazoles
BRPI0911681B8 (pt) 2008-04-23 2021-05-25 Rigel Pharmaceuticals Inc composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula in vitro
BRPI0917013A2 (pt) 2008-08-11 2016-02-16 Glaxosmithkline Llc métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
BRPI0917458A2 (pt) 2008-08-11 2015-12-01 Glaxosmithkline Llc composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
EP2322515B1 (fr) * 2008-08-29 2016-04-20 JSR Corporation Procédé pour la préparation d'un anhydride d'un N-carboxy aminoacide ou d'un carbamate d'un aminoacide
JP2012503005A (ja) * 2008-09-19 2012-02-02 インスティテュート フォア ワンワールド ヘルス イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
EP2375899B1 (fr) 2009-01-12 2015-02-25 Array Biopharma Inc. Composés contenant de la pipéridine et leur utilisation dans le traitement du diabète
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
US20120045459A1 (en) * 2009-05-05 2012-02-23 Van Andel Research Institute Methods for Treating Autophagy-Related Disorders
AR076936A1 (es) 2009-06-02 2011-07-20 Vitae Pharmaceuticals Inc Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
WO2011011652A1 (fr) 2009-07-24 2011-01-27 Glaxosmithkline Llc Composés thérapeutiques
US8729095B2 (en) 2009-08-28 2014-05-20 Daiichi Sankyo Company, Limited 3-(biaryloxy)propionic acid derivatives for prevention and/or treatment of thromboembolic diseases
CN106220623A (zh) 2009-11-06 2016-12-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
WO2011098451A1 (fr) 2010-02-10 2011-08-18 Glaxosmithkline Llc Dérivés de purine et leurs utilisations pharmaceutiques
DK2534149T3 (da) 2010-02-10 2015-01-05 Glaxosmithkline Llc 6-amino-2-{ [ (1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-on-maleat
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
FR2962649B1 (fr) * 2010-07-19 2025-10-24 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
KR101923367B1 (ko) 2011-02-02 2018-12-04 버텍스 파마슈티칼스 인코포레이티드 이온 채널의 조절제로서의 피롤로피라진―스피로사이클릭 피페리딘 아미드
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MX2013009393A (es) 2011-02-18 2013-08-29 Vertex Pharma Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
CN103517910B (zh) 2011-03-14 2016-12-14 沃泰克斯药物股份有限公司 作为离子通道调节剂的吗啉-螺环哌啶酰胺
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
LT6064B (lt) 2012-10-15 2014-08-25 Vilniaus Universitetas Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai
TW201441193A (zh) * 2012-12-06 2014-11-01 Kyowa Hakko Kirin Co Ltd 吡啶酮化合物
WO2014102594A2 (fr) * 2012-12-27 2014-07-03 Purdue Pharma L.P. Composés de pipéridine de type benzimidazole substitué et leurs utilisations
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
WO2014139144A1 (fr) * 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Composés et compositions thérapeutiques
EP3038617A1 (fr) * 2013-08-30 2016-07-06 Ramot at Tel-Aviv University Ltd. Méthode pour traiter la sclérose latérale amyotrophique par inhibition de la signalisation cxcr4/cxcl12
CN103497162B (zh) * 2013-09-24 2015-08-26 西安近代化学研究所 2-(4,6-二甲基嘧啶-2-基氨基甲酰氨基磺酰基)苯甲酸甲酯的合成方法
US8853407B1 (en) * 2013-12-07 2014-10-07 Muhammed Majeed Synthesis of 4-aryl 4-acyl piperidine, its salts and analogs using indium metal
KR20160124157A (ko) 2014-02-20 2016-10-26 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체
RU2016149812A (ru) 2014-06-06 2018-07-17 Флексус Байосайенсиз, Инк. Иммунорегулирующие средства
JP6633618B2 (ja) 2014-08-21 2020-01-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 強力なｒｏｃｋ阻害剤としてのタイドバックのベンズアミド誘導体
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
BR112017008809A2 (pt) 2014-11-05 2017-12-19 Flexus Biosciences Inc agentes imunorreguladores
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
MX2017006302A (es) 2014-11-13 2018-02-16 Glaxosmithkline Biologicals Sa Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
JP6653319B2 (ja) 2015-03-30 2020-02-26 武田薬品工業株式会社 複素環化合物
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
LT6401B (lt) 2015-07-28 2017-06-12 Vilniaus Universitetas Karboanhidrazės selektyvūs inhibitoriai
BR112018008630A2 (pt) * 2015-11-06 2018-10-30 Neurocrine Biosciences Inc derivados de n-[2-(1-benzilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazina-1-carboxamida, seus usos, composição farmacêutica
CN107849084B (zh) 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
PT3440076T (pt) 2016-04-07 2022-07-29 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas úteis como modeladores de proteína
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018106945A1 (fr) 2016-12-07 2018-06-14 Progenity Inc. Procédés, dispositifs et systèmes de détection du tractus gastro-intestinal
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3554541B1 (fr) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Traitement d'une maladie du tractus gastro-intestinal avec une chimoikine/un inhibiteur du récepteur de chimiokine
CA3077337A1 (fr) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulateurs de stimulateur des genes (sting) de l'interferon
AU2018344902B2 (en) 2017-10-05 2021-06-03 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING) useful in treating HIV
BR112020013073A2 (pt) * 2017-12-29 2020-12-01 Biomarin Pharmaceutical Inc. composto, composto, estereoisômero único ou mistura de estereoisômeros ou sal farmaceuticamente aceitável, composição farmacêutica, método de tratamento de uma doença ou distúrbio e composto ou sal farmaceuticamente aceitável do mesmo
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
EP3883635A1 (fr) 2018-11-19 2021-09-29 Progenity, Inc. Méthodes et dispositifs pour traiter une maladie au moyen d'une biothérapie
US20220227761A1 (en) 2019-05-16 2022-07-21 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
WO2020232378A1 (fr) 2019-05-16 2020-11-19 Silicon Swat, Inc. Dérivés d'acide acétique benzo[b][1,8]naphtyridine et leur procédés d'utilisation
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
US12486250B2 (en) 2019-12-06 2025-12-02 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
EP4077318B1 (fr) 2019-12-18 2025-10-15 Ctxt Pty Ltd Dimères de benzimidazole en tant que modulateurs de sting
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CN117776958A (zh) * 2023-12-06 2024-03-29 华南理工大学 一种芳烃羧酸间位烷基化产物及其合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2248018A (en) 1939-03-30 1941-07-01 Winthrop Chem Co Inc 4-aryl-piperidine-ketones and a process of preparing them
US2773870A (en) * 1953-06-04 1956-12-11 Sterling Drag Inc 1-(lower alkyl)-4-phenyl-4-(tertiaryaminoalkoxymethyl- and tertiary-aminoalkoxy) piperidines and their preparation
NL130088C (fr) * 1960-03-14
US3334106A (en) * 1964-10-20 1967-08-01 Aldrich Chem Co Inc N(aryl)n(hydrocarbyl)-omega-(4-phenyl-4-piperidinocarbonylheteroamine) alkanoamide
US3539580A (en) * 1967-06-26 1970-11-10 Janssen Pharm 4-aryl-4-aminoalkoxy-piperidines
ZA852235B (en) * 1984-03-26 1986-11-26 Janssen Pharmaceutica Nv Anti-virally active pyridazinamines
SE8904298D0 (sv) * 1989-12-21 1989-12-21 Astra Ab New compounds
FR2676055B1 (fr) 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
SE9400447D0 (sv) * 1994-02-11 1994-02-11 Astra Ab New compounds
AU5604998A (en) * 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025605A1 (fr) * 1996-12-13 1998-06-18 Merck & Co., Inc. Azacycles spiro-substitues utilises comme modulateurs de l'activite des recepteurs de la chemokine
CN1172932C (zh) * 1997-06-17 2004-10-27 先灵公司 抑制法尼基蛋白转移酶的苯并(5,6)芳庚并(1,2b)吡啶衍生物
CA2296314A1 (fr) * 1997-07-25 1999-02-04 Merck & Co., Inc. Amines cycliques modulant l'activite des recepteurs de chimiokines
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
BR0009338A (pt) * 1999-03-26 2001-12-26 Astrazeneca Ab Composto, processo para a preparação do mesmo,composição farmacêutica, processo para apreparação da mesma, uso de um composto, e,método de tratamento de uma doençainflamatória em um paciente sofrendo ou em riscode dita doença
KR100439357B1 (ko) * 1999-05-04 2004-07-07 쉐링 코포레이션 Ｃｃｒ５ 길항제로서 유용한 피페리딘 유도체
GB0107907D0 (en) * 2001-03-29 2001-05-23 Smithkline Beecham Plc Novel compounds
JP2002348288A (ja) * 2001-05-28 2002-12-04 Ono Pharmaceut Co Ltd スピロ複素環誘導体およびそれらを有効成分とする薬剤
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function

Also Published As

Publication number Publication date
CN1744899A (zh) 2006-03-08
JP2006511554A (ja) 2006-04-06
ZA200505600B (en) 2006-09-27
AU2003300902A1 (en) 2004-07-09
WO2004054974A2 (fr) 2004-07-01
BR0317230A (pt) 2005-10-25
MXPA05006354A (es) 2005-08-26
WO2004054974A3 (fr) 2004-09-02
RU2005118407A (ru) 2006-03-10
US7645771B2 (en) 2010-01-12
NO20052739L (no) 2005-08-19
CO5580771A2 (es) 2005-11-30
EP1569646A2 (fr) 2005-09-07
CA2509711A1 (fr) 2004-07-01
NO20052739D0 (no) 2005-06-07
US20060229336A1 (en) 2006-10-12
KR20050087832A (ko) 2005-08-31

Similar Documents

Publication Publication Date Title
MA27647A1 (fr) Antagonistes de ccr5 utiles comme agents therapeutiques
MA27009A1 (fr) Derives de pyrazole pour le traitement d&#39;une infection par le vih
MA27990A1 (fr) Derives de piperazine pour le traitement d&#39;infections par le vih
ATE405269T1 (de) Cyclohexylverbindungen als ccr5-antagonisten
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
DE60318891D1 (de) Cyclopropylverbindungen als ccr5 antagonisten
TNSN05104A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
DE60322423D1 (de) Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten
MA31949B1 (fr) Dérivés d&#39;aminotriazole comme agonistes d&#39;alx
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
MA26946A1 (fr) Derives de pyrazole nouveaux et leur utilisation comme inhibiteurs de proteine-kinases.
MA26864A1 (fr) Antagonistes du facteur de liberation de corticotrophine.
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
DE60324014D1 (de) Heterocyclische verbindungen alsccr5-antagonisten
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
DE60318874D1 (en) Pyrazolderivate
MA68743B1 (fr) Composés et compositions pour le traitement d&#39;états associés à l&#39;activité du récepteur de lpa
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l&#39;histamine
BR0314759A (pt) Derivados de pirazol
MA26705A1 (fr) Derives d&#39;hygromycine a nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA57215B1 (fr) Composés comprenant un nitrile comme antiviraux pour le traitement d&#39;une infection à coronavirus
TNSN05072A1 (fr) Derives de 4-(3,5-dicyanophenoxy) pyrazole destines a etre utilises comme modulateurs de transcriptase dans le traitement d&#39;affections provoquees par le vih
AU2003264940A1 (en) Pyrazole derivatives and their use as therapeutic agents for hiv mediated diseases